Progress in the research of axitinib in the treatment of renal cell carcinoma
- VernacularTitle:肾细胞癌治疗药--阿西替尼的研究进展
- Author:
Gui-Ying FU
1
Author Information
1. 解放军307医院 药剂科
- Keywords:
axitinib;
renal cell carcinoma;
tyrosine kinases inhibitor
- From:
The Chinese Journal of Clinical Pharmacology
2014;(4):371-373
- CountryChina
- Language:Chinese
-
Abstract:
Axitinib has been shown to inhibit receptor tyrosine kina-ses including vascular endothelial growth factor receptors VEGFR-1 , VEGFR-2, and VEGFR-3.On January 27, 2012, the US Food and Drug Administration approved axitinib tablets for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy.
